International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Arcutis Announces FDA Approval for ZORYVE (Roflumilast) Cream 0.3% for Plaque Psoriasis in Individuals Age 12 and Older

Arcutis Press Release Graphic

The United States Food and Drug Administration (FDA) announced on July 29 the approval of Arcutis’ ZORYVE™ (Roflumilast) cream 0.3% for the treatment of plaque psoriasis in individuals 12 years of age or older. ZORYVE is a once-daily, steroid-free cream approved to treat mild, moderate, and severe plaque psoriasis. ZORYVE™ has proven to provide patients with rapid clearance of plaques and reduction in itch in all affected areas of the body. This is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to be available mid-August.

arcutis

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Elevate Your Psoriasis Care and Boost Your Expertise: Join the IPC Psoriasis Masterclass for North America in Chicago

Getting to Know IPC’s Board Member André Carvalho: What Inspired Me to Specialize in Psoriasis

Beyond Skin-Deep: Tackling Gaps in Psoriasis Care

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.